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Abstract
Background—Interferon gamma release assays (IGRAs) are the first new diagnostic tests for 
latent tuberculosis (TB) infection (LTBI) since the century-old tuberculin skin test (TST). They are 
cell-mediated immune-based blood tests that have revolutionised LTBI diagnosis and are 
increasingly recommended by national guidelines.
Objectives—With the rapid expansion of the IGRA evidence-base in recent years, the limitations 
of IGRA and uncertainties in clinical interpretation of IGRA results have increasingly come into 
focus. In LTBI diagnosis these include: prognostic power of IGRAs relative to TST for quantifying 
risk of progression to active disease, false-negative rates in immunocompromised patients, the 
clinical meaning of IGRA reversion and the significance of the size of IGRA response. 
Furthermore, the role of IGRAs in the diagnostic work-up of active TB is unclear, and there is 
little evidence supporting use of the tests in anti-TB treatment monitoring.
Methodological approach—On-going large prospective longitudinal clinical endpoint cohort 
studies of active and latent TB will tackle some of the uncertainties regarding IGRAs. Here we 
discuss clinical practice and guidance in light of the current uncertainties, based on existing 
evidence.
Conclusions and impact—Current and planned clinical research will fill the gaps in the 
evidence-base, narrowing the areas of uncertainty and informing future policy. Translational 
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research into next-generation IGRAs and new T cell-based diagnostic platforms will likely 
overcome the limitations of current IGRAs in the near future.
Introduction
Mycobacterium tuberculosis (Mtb) causes almost 9 million cases of active tuberculosis (TB) 
annually, resulting in over 1.4 million deaths1; one-third of the world’s population is 
believed to be latently infected.2 The incidence of TB in the UK has risen over the last two 
decades3 and, in line with most high-income countries, the majority of cases occur in 
foreign-born individuals from high-incidence nations.
Individuals with latent TB infection (LTBI) comprise a large reservoir from which future 
active cases arise, but chemoprophylactic treatment can effectively prevent subsequent 
development of active TB. Diagnosis and treatment of LTBI is therefore a cornerstone of TB 
control in high-income low-incidence countries. Since the risk of progressing to active TB is 
highest within the first 2–3 years following infection,4 this strategy specifically targets 
recently exposed individuals as well as those with risk factors for increased risk of 
progression to active TB, in particular HIV-associated or iatrogenic immunosuppression.
Until recently the diagnosis of LTBI was dependent on the tuberculin skin test (TST), which 
suffers from poor specificity (due to confounding by prior BCG vaccination) and low 
sensitivity in immunocompromised patients. Interferon-gamma release assays (IGRAs) are 
blood tests developed to improve diagnosis by measuring the ex vivo cellular immune 
response to Mtb-specific antigens,5 and are commercially available as QuantiFERON®-TB 
Gold In-Tube (QFT-GIT) (Cellestis, Carnegie, Australia) and T-SPOT®.TB (Oxford 
Immunotec, Abingdon, UK). These tests are not confounded by prior BCG vaccination. A 
positive IGRA in someone with no clinical or radiological evidence of active TB thus 
constitutes a diagnosis of LTBI.
Published guidelines in most high-income low-incidence countries now recommend use of 
IGRAs in the diagnosis of Mtb infection,6 7 either in a two-step testing strategy where the 
IGRA is used to confirm Mtb infection in BCG-vaccinated persons who test positive by TST 
or as a single-step IGRA. However, there are several uncertainties in their clinical 
application and interpretation (table 1).
Uncertainties in Igra Testing
Latent TB
The central challenge of treatment for LTBI is identifying those with the highest risk of 
progression. Since only approximately 5% of TST-positive TB contacts progress to active 
TB within 2–5 years of exposure,4 the number of TST-positive contacts requiring treatment 
to prevent one case of active TB (number needed to treat, NNT) is about 20. Given that the 
TB burden in low-incidence countries is largely driven by LTBI progressing to active 
disease, a more powerfully predictive test to stratify latently infected individuals by 
progression risk would improve targeting of preventive treatment thereby reducing the NNT.
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Several longitudinal studies have confirmed that IGRAs predict progression from LTBI to 
active TB. However, their prognostic power compared with the TST has been a key area of 
uncertainty. One systematic review of 15 studies with 26 680 individuals concluded that the 
prognostic power of IGRAs and the TST were low and broadly equivalent,8 while another 
review of 28 studies including >30 000 individuals found IGRAs to be more predictive than 
the TST.9 Updated guidelines from the National Institute for Health and Clinical Excellence 
(NICE) on the use of IGRAs10 highlighted the paucity of high-quality studies of the 
prognostic power of IGRAs relevant to low-incidence settings on which to base clinical 
recommendations.
A new study published in this issue of Thorax makes an important contribution to this 
evidence base and may help to inform IGRA-based screening policies.11 A single-step QFT-
GIT screening strategy in 1769 recent TB contacts was evaluated in routine practice in 
Leicester, UK. Among untreated contacts, QFT-GIT had 70% sensitivity and 86% specificity 
for identifying LTBI progressing to active disease in 2 years, and the NNT of QFT-positive 
cases to prevent one case of active TB was 7, substantially lower than previously reported 
for the TST. This figure needs to be interpreted with caution, however, as it is lower than that 
reported by almost all previous studies and meta-analyses and may reflect inherent bias in 
the study design because the investigators making the diagnoses were not blinded to the 
IGRA results. Nonetheless, the study shows promise for the use of IGRAs in contact 
investigations to improve targeting of preventive therapy. However, IGRA results were not 
predictive of progression to disease in older contacts (≥36 years), most likely due to a higher 
burden of infection that was remotely acquired (and therefore less likely to progress) in this 
mostly foreign-born population, analogous to the disappointing prognostic power of IGRAs 
in contacts in high-burden countries.
Available longitudinal outcome data and the higher specificity of IGRAs collectively suggest 
that the NNT for IGRA-positive contacts is lower than for TST-positive contacts, but most 
available evidence suggests it is still far from that required to effect a step change in TB 
control and prevention. Enhancing the prognostic power of IGRAs, thereby reducing the 
NNT, is therefore an urgent research priority (box 1).
Since recently infected contacts are at higher risk of progression to active TB, a test able to 
distinguish recently acquired infection from remotely acquired infection would substantially 
reduce the NNT. Neither IGRAs nor the TST are capable of this discrimination,12 13 and 
targeting recently infected persons will continue to depend on epidemiological risk factors 
until such a test is developed.
Some studies suggest that a larger size of baseline IGRA response may be predictive of 
progression,14 but there are currently insufficient data to use this clinically to risk-stratify, 
and more data correlating quantitative baseline responses with clinical outcomes are 
required (box 1). Therefore, results should currently only be interpreted in a binary fashion 
as positive or negative. Borderline results are uninterpretable and have no clinical 
significance, and should therefore be repeated. Indeterminate results, which usually result 
from a failed positive control and are more common in the setting of suppressed cellular 
immunity, are also uninterpretable and should also be repeated.
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Where IGRAs are repeated, results may change from positive to negative or vice versa.15 16 
Conversion from negative to positive has similar clinical implications to TST conversion, 
reflecting recent acquisition of infection. The clinical significance of reversion from positive 
to negative is uncertain, although it may reflect spontaneous clearance of infection and low/
absent risk of progression. Only longitudinal clinical outcome studies will determine if this 
is the case (box 1).
Active TB
IGRAs measure a cellular immune response to Mtb-specific antigens. A positive result 
therefore indicates infection, but does not distinguish active from latent TB. Since Mtb 
infection is a prerequisite for TB disease, a negative IGRA result might provide a rapid 
‘rule-out’ for active TB. However, this requires very high diagnostic sensitivity and, 
although IGRAs may have higher sensitivity than the TST, neither is sensitive enough to 
exclude a diagnosis of active TB.17 18
It is also proposed that a positive IGRA may provide a useful adjunct to ‘rule-in’ the 
diagnosis in paediatric patients with a clinical picture consistent with active TB, as the TST 
is already used.19 Furthermore, NICE guidelines suggest that TST/IGRA can be beneficial 
in diagnosing cases where histological appearances are not conclusive during the 
investigation of non-pulmonary TB.20 Clinical studies already indicate that next-generation 
IGRAs, incorporating additional Mtb antigens or measuring additional Mtb-induced 
cytokines, provide significantly improved diagnostic sensitivity (without compromising 
specificity) that could enable rapid rule-out of suspected active TB (box 1).21 17 Newer T 
cell-based diagnostic platforms utilise T cell functional signatures that reflect mycobacterial 
burden to differentiate active from latent TB and provide treatment monitoring tools.22–24
Is Ongoing Research Likely To Resolve The Uncertainties?
The UK National Institute for Health Research Health Technology Assessment Programme 
(NIHR HTA) UK Prognostic Evaluation of Diagnostic IGRA ConsorTium (PREDICT) 
study is a large cohort study in which 10 000 participants at high risk for LTBI (TB contacts 
and new entrants from high-incidence countries) are undergoing IGRA and TST and are then 
being followed up for 2–3 years to determine progression rates by baseline test result. A 
wide range of novel biomarkers, including next-generation IGRAs, are also being assessed 
to correlate baseline responses with clinical outcomes (box 1).
The NIHR HTA-funded IGRAs in Diagnostic Evaluation of Active TB (IDEA) study will 
assess the role of current and next-generation IGRAs in the diagnostic evaluation of 1012 
patients prospectively presenting with suspected active TB in routine NHS practice (box 1). 
Evidence-based diagnostic algorithms and care pathways will be developed and health 
economic analyses performed to quantify the clinical utility and cost-effectiveness of current 
and next-generation IGRAs in the diagnostic assessment of suspected active TB.
Additional studies to quantify and compare the predictive value of IGRAs include a 
European TBNET study currently taking place using available routinely collected data in 
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contacts (http://www.tb-net.org/content/view/22/53/) and a large prospective study, similar to 
PREDICT, planned by the US Centers for Disease Control and Prevention.
What Should We Do In The Light Of Uncertainty?
The current NICE guidelines10 20 take account of most of the uncertainty around the 
prognostic power of existing IGRAs (table 1) and should be followed until other studies are 
completed. Given the paucity of evidence on the prognostic power of IGRAs in young 
children and immunocompromised individuals and the risk of false-negative results, 
concurrent IGRA and TST are recommended by NICE in children aged <5 years and HIV-
positive individuals with a CD4 cell count of <200 cells/mm3. IGRAs should not be used in 
the diagnosis of active TB until tests of higher sensitivity are available.5
Current And Future Policy
Given that >75% of the UK’s TB burden is carried by foreign-born immigrants, and most of 
this is due to reactivation of LTBI within the first several years after arrival, tackling 
imported LTBI in new entrants is increasingly recognised as an attractive strategy to reverse 
the relentless rise in UK TB rates.25 Policy is evolving rapidly in this area in response to a 
growing evidence base. For new entrant screening, NICE recommends using chest x-rays 
and either the two-step TST with confirmatory IGRA or single-step IGRA. NICE recently 
substantially broadened its recommendations on which new entrants to screen from those 
who originate from sub-Saharan Africa to all those from countries with a TB incidence of 
>40/100 000, which is lower than some urban centres in the UK. Moreover, the requisite 
resources to screen such a high proportion of all new entrants are not available; 
overstretched TB services in parts of the UK with the highest TB burdens often lack 
sufficient resources to screen any new entrants.26 However, an intermediate screening 
threshold of TB incidence in the country of origin to preferentially target migrant subgroups
—such as those from the Indian subcontinent and sub-Saharan Africa who are most likely to 
have LTBI—is probably more cost-effective and pragmatic, as evidenced by a recent 
multicentre UK study.27
A study published in the current issue of Thorax provides further evidence to potentially 
inform policy on new entrant screening.28 First, it compared the cost-effectiveness of TST 
and each of the two IGRA platforms for new entrant screening and found that single-step 
testing is more cost-effective than two-step testing, particularly with QFT-GIT. Second, 
taken together with a previous new entrant screening study,29 it supports a recently 
proposed streamlined algorithm to new entrant LTBI screening, reserving chest radiography 
only for those testing positive by IGRA.25 This emerging approach, however, assumes that 
IGRA false-negative rates in contacts with asymptomatic active TB are very low, but more 
data are needed to support this.25 Third, it demonstrates that IGRA-based LTBI screening in 
immigrants can be reliably and cost-effectively carried out in primary care.28 However, due 
to variable levels of registration with general practitioners among migrants,30 
implementation of IGRA screening should be accompanied by a drive to encourage access 
to primary care.
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In conclusion, while several clinically important uncertainties remain, research is rapidly 
filling the gaps in the evidence base which, in turn, is informing policy and guiding practice.
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Box 1
Current National Institute for Health Research Health Technology 
Assessment (NIHR HTA)-funded research addressing interferon-gamma 
release assay (IGRA) uncertainties
Latent TB: PREDICT
Clinical uncertainty: Prognostic value of IGRA compared with the tuberculin skin test 
(TST) for predicting progression to active tuberculosis (TB)
Study design: Prospective longitudinal cohort
Population: New entrants and TB contacts
Intervention: Baseline IGRA
Outcome: Development of culture confirmed TB
Uncertainties addressed:
▸ Prognostic power of QFT-GIT vs T-SPOT®.TB vs TST
▸ Prognostic power of IGRAs in high-risk populations including HIV-infected 
participants
▸ Prognostic power of quantitative baseline IGRA responses
▸ Clinical significance of IGRA reversion
▸ Improved prognostic power of next-generation IGRAs
Active TB: IDEA
Clinical uncertainty: Clinical utility of IGRA in diagnostic work-up of active TB
Study design: Prospective longitudinal cohort
Population: NHS patients with suspected active TB
Intervention: Baseline IGRA
Outcome: Final diagnosis of active TB
Uncertainties addressed:
▸ Role of QFT-GIT vs T-SPOT®.TB vs TST
▸ If and where IGRAs fit in diagnostic algorithm for evaluation of suspected 
active TB
▸ Cost-effectiveness of diagnostic strategies
▸ Role of next-generation IGRAs in treatment monitoring
▸ Role of next-generation IGRAs in rapidly ruling out suspected active TB
▸ Role of next-generation IGRAs in treatment monitoring
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Table 1
Challenges in interpreting IGRA results in various clinical settings
Subgroups considered for IGRA testing by NICE Uncertainties of IGRAs
New entrants from high incidence countries Which immigrant subgroups to target?
Contacts of a TB outbreak Healthcare workers What is the meaning of reversion?
Healthcare workers
Adult contacts of active TB cases
Paediatric contacts of active TB cases* False negative rates unknown in high-risk populations
Immunocompromised patients*
Active TB† False negative rates in 15–25%
Active and latent TB: effect of treatment† Increased risk of false negative results
Unsuitable for treatment monitoring
*
NICE recommends testing with both IGRA and the tuberculin skin test.
†
NICE does not recommend IGRA testing but highlights potential uses which are the subject of further study.
IGRA, interferon gamma release assay; NICE, National Institute for Health and Clinical Excellence; TB, tuberculosis.
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